Founded in Denmark in 1923, Novo Nordisk now has production facilities in six countries, with affiliates or offices in 68 countries.
They also launched the Novo Nordisk Changing Diabetes World Tour — a truck that folds out into an educational and awareness-developing bus. The vehicle was launched in Copenhagen in September 2005 and has visited Europe, Africa, and Australia.
Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S.
- 1923 Nordisk Insulinlaboratorium (later Nordisk Gentofte) founded.
- 1925 Novo Terapeutisk Laboratorium (later Nordisk Industri) founded.
- 1932 Nordisk Insulinlaboratorium founds the Steno Memorial Hospital.
- 1938 Novo founds Hvidøre Diabetes Sanatorium.
- 1946 Nordisk develops Isophane insulin NPH insulin, a neutral insulin with prolonged action.
- 1953 Lente – a long-acting insulin zinc suspension – is launched.
- 1973 Monocomponent (MC) insulin is introduced – the purest insulin available.
- 1982 Human monocomponent insulin is launched – the world’s first insulin preparation identical to human insulin. It is extracted from the pancreas of pigs and converted to human insulin.
- 1985 NovoPen – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched.
- 1987 Novo starts production of human insulin with the help of genetically engineered yeast cells.
- 1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become the world’s leading producer of insulin.
- 1989 NovoLet – the world’s first prefilled insulin syringe – is marketed.
- 1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
- 1998 NovoNorm/Prandin, a new oral treatment for type 2 diabetes, is launched in the US and a number of European countries.
- 1999 Innovo, the world’s first insulin doser with a built-in electronic memory, is launched in Europe.
- 1999 NovoRapid (NovoLog in the US) – the first rapid-acting insulin analogue – is marketed.
- 2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S.
- 2001 InnoLet – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched.
- 2001 InDuo – the world’s first combined blood glucose monitor and insulin injection system – is introduced.
- 2001 NovoRapid FlexPen and Insulatard FlexPens, prefilled pens designed to be easy and discreet to use, are marketed.
- 2001 Novo Nordisk acquires the controlling interest in the Brazilian pharmaceutical company Biobrás.
- 2002 NovoMix 30 FlexPen, a dual-release insulin analogue, is released.
- 2004 Levemir – a long-acting insulin analogue – is launched.